Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypofractionated accelerated radiotherapy in osteogenic sarcoma.

F Lombardi1, L Gandola, F Fossati-Bellani

  • 1Division of Radiotherapy, Istituto Nazionale Tumori, Milan, Italy.

International Journal of Radiation Oncology, Biology, Physics
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A lysate of a multi-strain probiotic formulation inhibits cell growth and oxidative phosphorylation in colorectal cancer cells via a ceramide-mediated mechanism.

Beneficial microbes·2026
Same author

Search for Light Pseudoscalar Bosons, Pair-Produced in Higgs Boson Decays in the Four-Electron Final State in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2026
Same author

Observation of Suppressed Charged-Particle Production in Ultrarelativistic Oxygen-Oxygen Collisions.

Physical review letters·2026
Same author

Challenging Spontaneous Quantum Collapse with the XENONnT Dark Matter Detector.

Physical review letters·2026
Same author

Measurement of D^{0} Meson Photoproduction in Ultraperipheral Heavy Ion Collisions.

Physical review letters·2026
Same author

Observation of tWZ Production at the CMS Experiment.

Physical review letters·2026
Same journal

Highly Variable, Complex, and Contextual: The Business of Radiation Oncology Practice.

International journal of radiation oncology, biology, physics·2026
Same journal

Corrigendum to 'Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation' [International Journal of Radiation Oncology*Biology*Physics Volume 112, Issue 5, 1 April 2022, Pages 1243-1255].

International journal of radiation oncology, biology, physics·2026
Same journal

Multicenter external validation of normal tissue complication probability models for radiation-induced primary hypothyroidism in head and neck cancer survivors with long-term endocrine outcomes.

International journal of radiation oncology, biology, physics·2026
Same journal

THGEM-Based Air Ionization Chamber for Online Dose Monitoring in Conventional and FLASH Radiotherapy.

International journal of radiation oncology, biology, physics·2026
Same journal

Single Percussive Ventilation Breath-hold Imaging and Delivery in Lung Tumor Stereotactic Ablative Radiation Therapy: Initial Observations From a Prospective Clinical Trial.

International journal of radiation oncology, biology, physics·2026
Same journal

Proton beam therapy in nonmetastatic rhabdomyosarcoma: Outcome, prognostic factors and the effect of timing of radiation therapy.

International journal of radiation oncology, biology, physics·2026
See all related articles

Hypofractionated accelerated radiotherapy shows high response rates for osteogenic sarcoma, achieving durable remission in 81% of sites. While effective, this palliative treatment can cause severe normal tissue damage.

Area of Science:

  • Oncology
  • Radiotherapy
  • Skeletal Tumors

Background:

  • Osteogenic sarcoma is a rare primary bone cancer.
  • Palliative radiotherapy is used for symptom control in advanced disease.
  • Hypofractionated accelerated radiotherapy offers a concise treatment schedule.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of hypofractionated accelerated radiotherapy for osteogenic sarcoma.
  • To assess response rates in primary tumors and skeletal metastases.
  • To determine the impact of combined modality treatment with chemotherapy.

Main Methods:

  • A hypofractionated accelerated radiotherapy regimen (3 weekly fractions of 6 Gy over 2 weeks to 36 Gy) was employed.
  • Treatment was administered as a single modality or combined with chemotherapy.

Related Experiment Videos

  • Radiological assessment was used to evaluate treatment response and tumor necrosis.

    • Main Results:

    • A durable response was achieved in 81% of irradiated sites (17/21).
    • Combined modality treatment with chemotherapy yielded a 92% response rate (12/13).
    • High tumor necrosis rates (95-100%) were observed in patients undergoing surgery post-irradiation.

    Conclusions:

    • Hypofractionated accelerated radiotherapy is an effective palliative treatment for osteogenic sarcoma, inducing significant remission.
    • The regimen, especially when combined with chemotherapy, demonstrates high response and necrosis rates.
    • Severe normal tissue toxicity is a notable concern with this radiotherapy approach.